Dennis A. Smith

发表

Is pharmaceutical R&D just a game of chance or can strategy make a difference?

Esther F. Schmid, Dennis A. Smith, Dennis A Smith, 2004, Drug discovery today.

Keynote review: Is declining innovation in the pharmaceutical industry a myth?

Esther F. Schmid, Dennis A. Smith, Dennis A Smith, 2005, Drug discovery today.

Drug withdrawals and the lessons within.

Esther F. Schmid, Dennis A. Smith, 2006, Current opinion in drug discovery & development.

Physicochemical Properties in Drug Metabolism and Pharmacokinetics

Dennis A. Smith, 2007 .

Managing the challenge of chemically reactive metabolites in drug development

Ian D. Wilson, Alan Boobis, Chris E. P. Goldring, 2011, Nature Reviews Drug Discovery.

Early Screening for ADMET Properties

Dennis A. Smith, 2010 .

Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates

Dennis A. Smith, M. Ackland, B. Jones, 1997 .

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Relevance of Half-Life in Drug Design.

T. Maurer, K. Beaumont, L. Di, 2017, Journal of medicinal chemistry.

Minireview Which Metabolites Circulate? s

Dennis A. Smith, D. Dalvie, C. Loi, 2013 .

Pathways of Reactive Metabolite Formation with Toxicophores/‐Structural Alerts

Deepak Dalvie, Amit S. Kalgutkar, A. Kalgutkar, 2012 .

Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK

Han van de Waterbeemd, H. Waterbeemd, D. Walker, 2006 .

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

Edward H. Kerns, Li Di, L. Di, 2010, Nature Reviews Drug Discovery.

Managing innovation in the pharmaceutical industry

Esther F. Schmid, Dennis A. Smith, 2005 .

Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics

Han van de Waterbeemd, H. Waterbeemd, K. Beaumont, 2001 .

Impact of target interactions on small-molecule drug disposition: an overlooked area

Malcolm Rowland, Andrés Olivares-Morales, Thierry Lavé, 2018, Nature Reviews Drug Discovery.

14. MIST AND THE FUTURE

B. K. Park, Dennis A. Smith, B. Park, 2016 .

Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward

Alexander Alex, A. Alex, Dennis A. Smith, 2015 .

SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV

Samantha Abel, D. Walker, Dennis A. Smith, 2005, Drug Metabolism and Disposition.

Importance of target-mediated drug disposition for small molecules.

Malcolm Rowland, Andrés Olivares-Morales, Thierry Lavé, 2018, Drug discovery today.

Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics

Barry C. Jones, Dennis A. Smith, M. Ackland, 1997 .

Pharmacokinetics and metabolism in drug design

Han van de Waterbeemd, H. Waterbeemd, D. Walker, 2001 .

Volume of Distribution in Drug Design.

Li Di, Tristan S. Maurer, T. Maurer, 2015, Journal of medicinal chemistry.

The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols.

Dennis A. Smith, 2011, Bioanalysis.

The Impact of Technological Advances on Drug Discovery Today

K. James, Esther F. Schmid, Dennis A. Smith, 2001 .

An in vitro toolbox to accelerate anti-malarial drug discovery and development

David M. Shackleford, Dennis A. Smith, S. Charman, 2020, Malaria Journal.

Intrinsically Electrophilic Compounds as a Liability in Drug Discovery

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Role of Reactive Metabolites in Drug‐Induced Toxicity – The Tale of Acetaminophen, Halothane, Hydralazine, and Tienilic Acid

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies

J. Stadler, Dennis A. Smith, R. Webster, 2007, Drug Metabolism and Disposition.

Experimental Approaches to Reactive Metabolite Detection

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Citation

Alessandro, Serge, Tyler B. Hughes, 2016 .

Role of Reactive Metabolites in Pharmacological Action

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Drug-drug interactions for UGT substrates: a pharmacokinetic explanation for typically observed low exposure (AUC i /AUC) ratios

Dennis A. Smith, J. Williams, J. Koup, 2004 .

Pharmacokinetic investigation into the mechanism of toxicity of Furosemide and its thiophene analogue

Dominic P. Williams, Dennis A. Smith, I. Gardner, 2009 .

An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver

Dennis A. Smith, B. Jones, '. RACHELC.HALLIDAY, 2006 .

Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity.

Dominic P. Williams, R. Obach, B. K. Park, 2009, Chemico-biological interactions.

Bioactivation and Inactivation of Cytochrome P450 and Other Drug‐Metabolizing Enzymes

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Consequences of Bioisosteric Replacement

David S. Millan, Dennis A. Smith, 2012 .

Chemistry and enzymology: Their use in the prediction of human drug metabolism

Dennis A. Smith, 1994 .

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D. Walker, Dennis A. Smith, B. Jones, 1996, Medicinal research reviews.

A new phase of drug discovery? The rise of PK/PD means extremely challenging work at the coalface.

Dennis A. Smith, 2015, Bioanalysis.

Pfizer Sandwich Laboratories: where drug metabolism first met drug discovery

Dennis A. Smith, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance

P. Doležel, P. Mlejnek, Dennis A. Smith, 2019, Biomolecules.

When and How to Apply ADMET Principles to Drug Discovery and Development

Dennis A. Smith, 2012 .

Discovery and ADMET: Where are we now.

Dennis A. Smith, 2011, Current topics in medicinal chemistry.

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Manuel Llinás, George Papadatos, Sundari Suresh, 2016, PLoS pathogens.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D A Smith, D K Walker, D. Walker, 1996, Medicinal research reviews.

An Introduction to Pharmacokinetics

Dennis A. Smith, B. Clark, 1981 .

Role of Reactive Metabolites in Genotoxicity

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Which Metabolites Circulate?

Dennis A. Smith, D. Dalvie, C. Loi, 2013, Drug Metabolism and Disposition.

Which Metabolites Circulate ? s

Dennis A. Smith, D. Dalvie, C. Loi, 2013 .

The sulfonamide group as a structural alert: A distorted story?

Dennis A. Smith, Rhys M. Jones, 2008, Current opinion in drug discovery & development.

Cytochrome P450 and its Place in Drug Discovery and Development

Dennis A. Smith, 2003 .

Metabolic (Hepatic) Clearance

H. Waterbeemd, D. Walker, Dennis A. Smith, 2001 .

Metabolism, pharmacokinetics and toxicity of functional groups : impact of chemical building blocks on ADMET

Dennis A. Smith, 2010 .

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

R. Price, K. Chibale, Dale Taylor, 2018, Antimicrobial Agents and Chemotherapy.

P-glycoprotein related drug interactions: clinical importance and a consideration of disease states

Caroline A. Lee, Dennis A. Smith, E. Reyner, 2010, Expert opinion on drug metabolism & toxicology.

Physicochemistry and the Off‐Target Effects of Drug Molecules

Dennis A. Smith, 2016 .

Origin and Historical Perspective on Reactive Metabolites

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

1 Origin and Historical Perspective on Reactive Metabolites

Dennis A. Smith, 2012 .

Compound Attrition in Phase II/III

Wilma W Keighley, A. Alex, Dennis A. Smith, 2015 .

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

David M. Shackleford, R. Price, D. Fidock, 2017, Nature Communications.

What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

R. Obach, Dennis A. Smith, S. Roffey, 2007, Drug metabolism reviews.

Mitigating Toxicity Risks with Affinity Labeling Drug Candidates

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Design of drugs through a consideration of drug metabolism and pharmacokinetics

Dennis A. Smith, 1994, European Journal of Drug Metabolism and Pharmacokinetics.

Evolution of ADME science: where else can modeling and simulation contribute?

Dennis A. Smith, Dennis A Smith, 2013, Molecular pharmaceutics.

Bioactivation and Natural Products

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

Deepak Dalvie, Angus Nedderman, R Scott Obach, 2009, Chemical research in toxicology.

Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.

R Scott Obach, R. Obach, Dennis A. Smith, 2009, Chemical research in toxicology.

Case Studies on Eliminating/Reducing Reactive Metabolite Formation in Drug Discovery

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Clearance in Drug Design.

T. Maurer, K. Beaumont, L. Di, 2018, Journal of medicinal chemistry.

Pharmacokinetics and Metabolism in Drug Design: Smith: Pharmacokinetics

H. Waterbeemd, D. Walker, Dennis A. Smith, 2001 .

Communicating the risks and benefits of medicines.

Esther F. Schmid, Dennis A. Smith, S. Ryder, 2007, Drug discovery today.

Lipophilicity in PK design: methyl, ethyl, futile

Han van de Waterbeemd, Dennis A. Smith, Barry C. Jones, 2001, J. Comput. Aided Mol. Des..

R&D technology investments: misguided and expensive or a better way to discover medicines?

Esther F. Schmid, Dennis A. Smith, Dennis A Smith, 2006, Drug discovery today.

Dose Predictions for Drug Design.

T. Maurer, K. Beaumont, L. Di, 2020, Journal of medicinal chemistry.

Safety Assessment of Acyl Glucuronides—A Simplified Paradigm

T. Hammond, T. Baillie, Dennis A. Smith, 2018, Drug Metabolism and Disposition.

Discovery, innovation and the cyclical nature of the pharmaceutical business.

Esther F. Schmid, Dennis A. Smith, Dennis A Smith, 2002, Drug discovery today.

Dealing with Reactive Metabolite–Positive Compounds in Drug Discovery

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Metabolismand clearance of proxicromil — Studies in rat, hamster, rabbit, dog, squirrel monkey, cynomolgus monkey, baboon and man

Dennis A. Smith, M. G. Neale, 1983, European journal of drug metabolism and pharmacokinetics.

Multiple factors govern the association between pharmacology and toxicity in a class of drugs: toward a unification of class effect terminology.

Dennis A. Smith, P. Morgan, A. Harrison, 2011, Chemical research in toxicology.

Commentary on variability in vitamin K antagonist metabolism

Dennis A. Smith, 2006, Expert opinion on drug metabolism & toxicology.

Why do metabolites circulate?

Dennis A. Smith, D. Dalvie, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and Metabolism in Drug Design: SMITH:PHARMACOKINETICS 3E O-BK

H. Waterbeemd, A. Kalgutkar, D. Walker, 2012 .

Should scientific innovation be managed?

Esther F. Schmid, Dennis A. Smith, Dennis A Smith, 2002, Drug discovery today.

Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise

M. Rowland, Dennis A. Smith, 2019, Drug Metabolism and Disposition.

Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years.

Malcolm Rowland, Christian R Noe, C. Noe, 2012, Journal of pharmaceutical sciences.

SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING

R Scott Obach, R. Obach, Dennis A. Smith, 2005, Drug Metabolism and Disposition.

Pharmacokinetics in Early Drug Research

J B Houston, D A Smith, J H Fentem, 1997, Alternatives to laboratory animals : ATLA.

Are predictive biomarkers of toxicity worth having? An economic model

Esther F. Schmid, Dennis A. Smith, Byron Jones, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?

Dennis A Smith, Kevin Beaumont, K. Beaumont, 2009, Current opinion in drug discovery & development.

Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?

R. Obach, Dennis A. Smith, A. Nedderman, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

New bioanalytical technologies and concepts: worth the fuss?

Dennis A Smith, Dennis A. Smith, 2013, Bioanalysis.

A response to “radiolabelled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary”

R. Obach, Dennis A. Smith, A. Nedderman, 2013 .

Metabolites and safety: What are the concerns, and how should we address them?

R Scott Obach, R. Obach, Dennis A. Smith, 2006, Chemical research in toxicology.

Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.

Bo Feng, Ray Liu, Jack A Cook, 2010, Molecular pharmaceutics.

Retrospective Analysis of Structure–Toxicity Relationships of Drugs

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Metabolite Safety in Drug Development

Dennis A. Smith, S. Iverson, 2016 .

Reactive Drug Metabolites: KALGUTKAR:REACTIVE METAB.

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

Structural Alert and Reactive Metabolite Analysis for the Top 200 Drugs in the US Market by Prescription

A. Kalgutkar, R. Obach, Dennis A. Smith, 2012 .

INTRODUCTION: HISTORY OF METABOLITE SAFETY IN DRUG DEVELOPMENT

Dennis A. Smith, S. Iverson, 2016 .

Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.

D A Smith, D. Smith, Dennis A. Smith, 1992, Biochemical pharmacology.

A MIST conception: what has been learned from twenty years of human metabolite safety assessment?

R. Obach, Dennis A. Smith, D. Luffer-Atlas, 2023, Medicinal Chemistry Research.

Species differences in metabolism and pharmacokinetics: are we close to an understanding?

D. Smith, Dennis A. Smith, 1991, Drug metabolism reviews.

Do Drug Metabolism and Pharmacokinetic Departments Make Any Contribution to Drug Discovery?

Esther F. Schmid, Dennis A. Smith, B. Jones, 2002, Clinical pharmacokinetics.

Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise

M. Rowland, Dennis A. Smith, 2019, Drug Metabolism and Disposition.

Volume of Distribution in Drug Design.

T. Maurer, K. Beaumont, L. Di, 2015, Journal of medicinal chemistry.

Immunomodulatory therapies and the risk of opportunistic infections.

Dennis A. Smith, Dale E. Johnson, B. Park, 2010, Current opinion in drug discovery & development.

Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts.

E. Winzeler, K. Chibale, Dale Taylor, 2021, Journal of medicinal chemistry.